Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells
- 5 March 2018
- journal article
- research article
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 14 (3) , 385-397
Abstract
The aim of this study was to compare effect of everolimus on growth of different renal cell carcinoma (RCC) populations and develop experimental design to measure the early response of everolimus in clear cell RCC (ccRCC) cell lines including renal cancer stem cells. Effect of everolimus on RCC cell lines which include primary (786-0) and metastatic (ACHN) RCC cell lines as well as heterogenous populations of tumor cells of different histological RCC subtypes (clear cell RCC and papillary RCC) was measured when treated with everolimus in the range of 1–9 µM. Gene expression profiling using microarray was performed to determine the early response to everolimus in ccRCC cell lines after optimizing concentration of drug. Gene Set Enrichment Analysis (GSEA) was done which mainly focused on basic genes related to mTOR, hormonal and metabolic pathways. Everolimus acts on RCC cells in a dose—dependent manner. In all examined cell lines IC50 dose was possible to calculate after the third day of treatment. In ccRCC lines (parental and stem cell) everolimus changes expression of mTOR complexes elements and elements of related pathways when treated with optimized doses of drug. Characteristic expression profile for ccRCC cells at an early exposure time to everolimus is to elucidate. Wevarie include some basic observations derived from data analysis in the context of mechanism of action of drug with a view to better understand biology of renal cancer cells.Keywords
Funding Information
- Ministry of Science and Higher Education “Diamond grant” (DI2012007842)
This publication has 35 references indexed in Scilit:
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Multilevel Genomics-Based Taxonomy of Renal Cell CarcinomaCell Reports, 2016
- Renal Cancer Stem Cells: Characterization and Targeted TherapiesStem Cells International, 2016
- Current approaches in identification and isolation of human renal cell carcinoma cancer stem cellsStem Cell Research & Therapy, 2015
- Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyBMC Cancer, 2015
- Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: A tale of two complexesAdvances in Biological Regulation, 2015
- Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic featuresChinese Journal of Cancer, 2013
- Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with RapamycinMolecular and Cellular Biology, 2009
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase InhibitorClinical Cancer Research, 2009
- The evolving experience using everolimus in clinical transplantationTransplantation Proceedings, 2004